Adaptative MR-Guided Stereotactic Body Radiotherapy of Liver Tumors
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Radiotherapy
- Type
- Interventional
- Phase
- Not Applicable
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
The MRI guided stereotactic radiotherapy of hepatic lesions with an MRIdian® Linac tested in this study will allow: to see the tumor target in live with a non-irradiating imaging a reduction of the volume of non-tumor liver irradiated at high doses An progession of the dose delivered to the tumor le...
The MRI guided stereotactic radiotherapy of hepatic lesions with an MRIdian® Linac tested in this study will allow: to see the tumor target in live with a non-irradiating imaging a reduction of the volume of non-tumor liver irradiated at high doses An progession of the dose delivered to the tumor lesion to allow tumor control to be increased. a new dosimetric plan adapted each day to the new contours to avoid a risk of severe digestive toxicity while ensuring optimal treatment, at an appropriate dose, of the tumor volume.
Tracking Information
- NCT #
- NCT04242342
- Collaborators
- Not Provided
- Investigators
- Not Provided